WA-AGC-BIOLOGICS
24.1.2023 14:57:36 CET | Business Wire | Press release
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new commercial manufacturing project at its Seattle protein biologics manufacturing site. The CDMO is producing TZIELD™ (teplizumab-mzwv), a new T1D treatment from Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases.
Provention Bio chose AGC Biologics to manufacture TZIELD after the CDMO helped guide the product through PPQ manufacturing and validation batches, and United States Food and Drug Administration (FDA) approval. More than 1.8 million Americans have T1D, an autoimmune disease caused by the destruction of beta cells. TZIELD is the first and only immunomodulatory treatment that delays the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older. Patients who progress to Stage 3 T1D will eventually require insulin injections for life.
“The multi-year process of shepherding a new therapy from clinical research to commercial launch requires the collaboration of multiple partners, and we are grateful for the ongoing strategic collaboration of AGC Biologics as we begin to deliver TZIELD to patients,” said Provention Bio CEO Ashleigh Palmer. “This is an important milestone for the Type 1 Diabetes community, and we hope the launch of this therapy can truly make an impact on patients and families seeking innovative treatments for the delay of Stage 3 T1D.”
AGC Biologics runs multiple mammalian cGMP manufacturing lines and a variety of scales at its Seattle facility. The campus serves as a center of excellence for formulation and employs the latest fed-batch and perfusion manufacturing processes and houses a new microbial-based manufacturing line system. The AGC Biologics Seattle campus has produced biologics products for 30 years and has a long history of successful inspections by the FDA and commercial production.
“Congratulations to Provention Bio on this game-changing achievement for T1D patients,” said Kevin Ingham, General Manager of AGC Biologics’ Seattle site. “We at AGC Biologics are proud to have helped develop this innovative new medicine and to be manufacturing it for commercial distribution. This achievement demonstrates our Seattle site’s increasing track record in commercial manufacturing, which is aligned with AGC Biologic’s purpose of bringing hope to life.”
To learn more about AGC Biologics’ mammalian and microbial system-based biologics manufacturing site in Seattle, visit www.agcbio.com/facilities/seattle. For more information on the company’s Protein Biologics, Protein DNA (pDNA), Cell Therapy, Viral Vector and Messenger RNA (mRNA) drug product services visit www.agcbio.com.
About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including T1D, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005438/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Adtran launches Ensemble Cloudlet multi‑node to simplify high‑availability edge AI deployments8.4.2026 14:30:00 CEST | Press release
News summary: Enterprises and service providers need resilient, low-latency infrastructure to support emerging edge AI inference Ensemble Cloudlet multi-node creates high-availability edge clouds with distributed storage, starting from just two nodes Open platform with zero-touch deployment runs networking, security and AI workloads, including agentic AI applications Adtran today launched its Ensemble Cloudlet multi‑node solution, a high‑availability edge platform that supports AI inference and agentic AI deployments where low latency, resilience and secure local processing are critical. Removing the complexity and cost barriers that slow modern service and enterprise deployments, the solution creates a single, logical cloud with distributed storage and automated failover, starting with just two nodes. Built on Cloudlet OS and managed through Ensemble EdgeView orchestration, it enables zero-touch deployment and unified lifecycle management, providing a simple, scalable foundation for r
ZincFive Announces Nickel-Zinc Retrofit Kit to Modernize Existing UPS Energy Storage Infrastructure8.4.2026 14:05:00 CEST | Press release
A turnkey, safe, scalable drop-in upgrade for existing UPS systems with a long-life, sustainable alternative to lead-acid ZincFive®, the global leader in nickel-zinc (NiZn) battery-based solutions for immediate power applications, today announced the NiZn Retrofit Kit, an uninterruptible power supply (UPS) energy storage solution designed to bring the benefits of modern battery chemistry to existing UPS battery systems in mission-critical environments. The NiZn Retrofit Kit will enable data center operators and service providers to replace legacy valve-regulated lead-acid (VRLA) batteries with ZincFive’s long-life, high-performance nickel-zinc technology without requiring cabinet enclosure replacement, system redesign, or operational disruption. As data center power demands continue to increase, operators face growing pressure to improve reliability, reduce lifecycle costs, and meet sustainability targets. At the same time, much of the global UPS energy storage system installed base re
New Research Finds AI Is Now Foundational to Modern Marketing8.4.2026 14:00:00 CEST | Press release
AI’s Impact on Marketing Doubles as Teams Move from Experimentation to Embedded Use NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced its participation in a new marketing research study conducted by Callan Consulting, a Silicon Valley executive marketing consulting firm, joining 18 B2B and B2C technology companies to examine how AI is reshaping modern marketing organizations, marking a clear shift from early experimentation to embedded, enterprise‑wide adoption. According to the State of AI in Technology Marketing 2026 report, based on in‑depth interviews with CMOs and senior marketing leaders at the participating companies, the study finds that AI is becoming rapidly integrated across core marketing teams and workflows—from content development and research to campaign optimization and analytics. As adoption deepens, data quality, accessibility, and governance are emerging as critical priorities. "AI doesn't change what great marketing is supposed to
Sagard and Unigestion Announce Closing of Partnership Transaction8.4.2026 14:00:00 CEST | Press release
Transaction completion marks the formal expansion of a strengthened global platform: Sagard Private Equity Solutions Sagard, a global multi-strategy alternative asset management firm with over $45 billion USD1 in assets under management and Unigestion Private Equity Holding SA (UNG PE), a leading middle market private equity provider, today announced the successful closing of their combination transaction, originally announced in September. Completion of this transaction marks the formal launch of the partnership and the integration of UNG PE into Sagard’s global middle-market private equity platform, Sagard Private Equity Solutions (SPES). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408374851/en/ “We are thrilled to formally begin our partnership with the Unigestion team,” said Paul Desmarais III, Chairman & CEO of Sagard. “This milestone solidifies our joint commitment to building a global private equity platform pos
Telia to Deploy Seamless OS Following Acquisition of Telness Operator8.4.2026 13:16:00 CEST | Press release
Today, Nordic Communications Group AB, parent company of Telness Tech, announced it will divest its mobile virtual network operator (MVNO) Telness to Telia in Sweden. As part of the transaction, Telness will sign a long-term agreement with Telness Tech for continued use of the Seamless OS technology platform, ensuring a smooth digital customer experience. At closing, Telia will become the first mobile network operator (MNO) to deploy Seamless OS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408876675/en/ Telness Tech executive leadership team on the announcement that Telia will be the first Mobile Network Operator (MNO) deploying Seamless OS. From the left, Sergio Budkin; CRO, Martina Klingvall; Founder and CEO, Sebastian Stecki; CMO, Pablo Noguerol; COO, Christina Berggren; VP Customer, Delivery & Product, Jonas Cedenwing; Founder and CTO. "For Seamless OS to be brought into an MNO environment such as Telia's is a defi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom